E-LIB Suche - Ergebnisse für: E. E. Gubar

1

7 year of sacroiliac radiographic progression in early psor..:

E. Yu. Loginova ; P. O. Tremaskina ; E. E. Gubar...
https://rsp.mediar-press.net/rsp/article/view/3518/2353. , 2024

Link: https://rsp.mediar-press..

2

Results of a non-interventional observational multicenter s..:

T. V. Korotaeva ; E. E. Gubar ; E. Yu. Loginova...
https://mrj.ima-press.net/mrj/article/view/1498/1411. , 2023

Link: https://mrj.ima-press.ne..

3

Evaluation of the possibility of axial psoriatic arthritis ..:

E. E. Gubar ; T. V. Korotaeva ; Y. L. Korsakova...
https://rsp.mediar-press.net/rsp/article/view/3404/2309. , 2023

Link: https://rsp.mediar-press..

4

Prognostic factors associated with non-remission and low di..:

E. Yu. Loginova ; T. V. Korotaeva ; E. E. Gubar...
https://rsp.mediar-press.net/rsp/article/view/3441/2320. , 2023

Link: https://rsp.mediar-press..

5

Search for predictors of achieving minimal disease activity..:

L. D. Vorobyova ; T. V. Korotaeva ; S. I. Glukhova...
https://mrj.ima-press.net/mrj/article/view/1500/1414. , 2023

Link: https://mrj.ima-press.ne..

6

Clinical and instrumental characteristics of axial involvem..:

E. E. Gubar ; T. V. Korotaeva ; Yu. L. Korsakova...
https://rsp.mediar-press.net/rsp/article/view/3201/2215. , 2022

Link: https://rsp.mediar-press..

7

Impact of tofacitinib on patient-reported outcomes in patie..:

L. D. Vorobyeva ; T. V. Korotaeva ; E. Yu. Loginova...
https://rsp.mediar-press.net/rsp/article/view/3181/2195. , 2022

Link: https://rsp.mediar-press..

8

Axial involvement in psoriatic arthritis:

E. E. Gubar ; T. V. Korotaeva
https://rsp.mediar-press.net/rsp/article/view/3244. , 2022

Link: https://doi.org/10.47360..

9

Validation of the PsAID-12 Russian questionnaire in patient..:

L. D. Vorobyeva ; E. Yu. Loginova ; Yu. L. Korsakova...
https://rsp.mediar-press.net/rsp/article/view/3152. , 2022

Link: https://doi.org/10.47360..

10

Axial involvement in psoriatic arthritis ; Поражение позвон..:

E. E. Gubar ; T. V. Korotaeva ; Е. Е. Губарь.
https://rsp.mediar-press.net/rsp/article/view/3244/2240. , 2022

Link: https://rsp.mediar-press..

11

Impact of tofacitinib on patient-reported outcomes in patie..:

L. D. Vorobyeva ; T. V. Korotaeva ; E. Yu. Loginova...
https://rsp.mediar-press.net/rsp/article/view/3181. , 2022

Link: https://doi.org/10.47360..

12

2-years outcomes of the treat-to-target strategy in early p..:

E. Yu. Loginova ; T. V. Korotaeva ; E. E. Gubar...
https://rsp.mediar-press.net/rsp/article/view/3226. , 2022

Link: https://doi.org/10.47360..

13

2-years outcomes of the treat-to-target strategy in early p..:

E. Yu. Loginova ; T. V. Korotaeva ; E. E. Gubar...
https://rsp.mediar-press.net/rsp/article/view/3226/2230. , 2022

Link: https://rsp.mediar-press..

14

Prognostic factors associated with achieving minimal diseas..:

E. Yu. Loginova ; T. V. Korotaeva ; E. E. Gubar.
https://rsp.mediar-press.net/rsp/article/view/3253. , 2022

Link: https://doi.org/10.47360..

15

Validation of the PsAID-12 Russian questionnaire in patient..:

L. D. Vorobyeva ; E. Yu. Loginova ; Yu. L. Korsakova...
https://rsp.mediar-press.net/rsp/article/view/3152/2176. , 2022

Link: https://rsp.mediar-press..